however, AbbVie would be subject to a $1.6 billion break-up fee, payable to Shire. On 21 October, the merger was called off. Takeda takeover In April 2018, reported that Takeda Pharmaceutical Company had an approach to acquire Shire. Days later Shire announced they had rejected all three Takeda bids. The first bid valued the business at £41 billion (£28 per Shire shares paid in Takeda shares plus £16 per share in cash), the second £43 billion (£28.75 per Shire shares paid in Takeda shares plus £16.75 per share in cash) and the third £44 billion (£28 per Shire shares paid in Takeda shares plus £17.75 per share in cash). Reuters also reported interest from Allergan however they ruled themselves out a day later. A day later Takeda increased their offer with a fourth bid, to £26 per Shire shares paid in Takeda shares plus £21 per share in cash - giving a total value of £44.3 billion ($62.1 billion). On 24 April, Takeda submitted an enhanced fifth bid for the company. On 25 April, Shire said that they will recommend the revised £45.8 billion ($64 billion) offer to their shareholders. The enhanced offer included a more generous cash component, with the deal offering £21.76 ($30.33) in cash for each Shire ordinary share. The same day, GlaxoSmithKline ruled out making any form of counter-bid. On 8 May 2018, an agreement was finally reached in which Shire was sold to Takeda in a $62 billion deal. Takeda's acquisition of Shire closed on 8 January 2019. Acquisition history Shire Plc (Founded 1986, Acq 2019) Pharmavene (Acq 1997) Richwood Pharmaceutical Company (Acq 1997) Biochem Canada (Acq 2001) Transkaryotic Therapeutics (Acq 2005) New River Pharmaceuticals Inc (Acq 2007) Jerini (Acq 2008) Movetis (Acq 2012) Advanced BioHealing (Acq 2011) FerroKin BioSciences (Acq 2012) Lotus Tissue Repair, Inc (Acq 2013) Premacure AB (Acq 2013) SARcode Bioscience Inc (Acq 2013) ViroPharma (Founded 1994, Acq 2013) Lev Pharmaceuticals (Acq 2008) Fibrotech (Acq 2014) Lumena (Acq 2014) NPS Pharmaceuticals (Acq 2015) Meritage Pharma (Acq 2015) Foresight Biotherapeutics (Acq 2015) Dyax (Acq 2015) Baxalta (Acq 2016) Products The Annual Revenue figures in the following table were drawn from the company's 2015 preliminary results. Licences & Royalties In July 2014, Shire licensed the rights to the investigational Hunter syndrome compound, AGT-182, from ArmaGen for up to $225 million. The Annual Revenue figures in the following Table were drawn from the company's 2015